96.80 +0.62 (0.64%)
After hours: 5:56PM EST
|Bid||96.00 x 1100|
|Ask||96.99 x 1300|
|Day's range||94.99 - 97.00|
|52-week range||36.15 - 151.80|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||87.52|
You might have thought the coronavirus vaccine race ended when Pfizer (NYSE: PFE) crossed the finish line first in December. Variants from Brazil, the U.K., and South Africa worry the scientific community (and the rest of us) the most at the moment. Johnson & Johnson (NYSE: JNJ) highlighted exactly how its investigational vaccine performed against those new strains in its phase 3 trial.
If approved, the 50 million doses will be on top of the 407 million vaccine doses already secured by the government to date.
The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval.